First of its kind study pits psilocybin against a common antidepressant
1–10 of 50 posts
Re: First of its kind study pits psilocybin against a common antidepressant
#2Wasn't this tested 50 years ago and then sort of left dormant?
Re: First of its kind study pits psilocybin against a common antidepressant
#3Wasn't this tested 50 years ago and then sort of left dormant?
Psychedelic psychotherapy was left as a casualty to the war on drugs.
Re: First of its kind study pits psilocybin against a common antidepressant
#4Related prior discussion:
https://news.ycombinator.com/item?id=26816444
Re: First of its kind study pits psilocybin against a common antidepressant
#5> While members of the psychedelic cohort received 25 milligrams of psilocybin during the sessions, considered a medium-to-heavy dose of the drug, those in the antidepressant group received 1 milligram. Such a low dose is typically provided in psychedelic studies in lieu of a placebo
Doesn't seem like well-designed study.
Re: First of its kind study pits psilocybin against a common antidepressant
#6> “In hindsight I wish we’d made these other measures of well-being the primary outcome measure,” he said. “However the world — the Food and Drug Administration, the European Medicines Agency — doesn’t recognize those measures as valid.”
Am I understanding this correctly? Other academics are critical of the outcome measured, but it was specifically chosen because of recognition by national authorities.
Re: First of its kind study pits psilocybin against a common antidepressant
#7> While members of the psychedelic cohort received 25 milligrams of psilocybin during the sessions, considered a medium-to-heavy dose of the drug, those in the antidepressant group received 1 milligram. Such a low dose is typically provided in psychedelic studies in lieu of a placebo Doesn't seem like well-designed study.
Can you explain why for those of us unfamiliar?
Re: First of its kind study pits psilocybin against a common antidepressant
#8> While members of the psychedelic cohort received 25 milligrams of psilocybin during the sessions, considered a medium-to-heavy dose of the drug, those in the antidepressant group received 1 milligram. Such a low dose is typically provided in psychedelic studies in lieu of a placebo Doesn't seem like well-designed study.
Can you explain why for those of us unfamiliar?
Well it's not actually a placebo to start with.
Re: First of its kind study pits psilocybin against a common antidepressant
#9> While members of the psychedelic cohort received 25 milligrams of psilocybin during the sessions, considered a medium-to-heavy dose of the drug, those in the antidepressant group received 1 milligram. Such a low dose is typically provided in psychedelic studies in lieu of a placebo Doesn't seem like well-designed study.
Can you explain why for those of us unfamiliar?
I think the concern is that you could still be getting pharmacodynamic effects at 1mg, so the control wouldn’t really be a control.
It’s entirely feasible that you could get good results and limited side effects at dose x, and poor results overwhelmed by side effects at dose 25x.
Re: First of its kind study pits psilocybin against a common antidepressant
#10> “In hindsight I wish we’d made these other measures of well-being the primary outcome measure,” he said. “However the world — the Food and Drug Administration, the European Medicines Agency — doesn’t recognize those measures as valid.” Am I understanding this correctly? Other academics are critical of the outcome measured, but it was specifically chosen because of recognition by national authorities.
If I understood it correctly I took it to mean that the organizers of the study would have preferred to lean primarily on what government health agencies see as secondary or invalid measures of well-being.